Zhejiang Hisun Pharmaceutical Co Ltd (600267) — Capital Reinvestment Ratio
Zhejiang Hisun Pharmaceutical Co Ltd (600267) has a Capital Reinvestment Ratio of 0.23x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥438.43 Million) in capital expenditures (CN¥102.69 Million). Check Zhejiang Hisun Pharmaceutical Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhejiang Hisun Pharmaceutical Co Ltd Capital Reinvestment Ratio (1999–2025)
This chart tracks Zhejiang Hisun Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 27 annual periods. For the full cash flow conversion analysis, see 600267 cash flow metrics.
Annual Capital Reinvestment Ratio for Zhejiang Hisun Pharmaceutical Co Ltd (1999–2025)
Year-by-year Capital Reinvestment Ratio for Zhejiang Hisun Pharmaceutical Co Ltd from 1999 to 2025. See Zhejiang Hisun Pharmaceutical Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.19x | CN¥2.03 Billion | CN¥376.40 Million | ▲ +64.3% |
| 2024 | 0.11x | CN¥2.11 Billion | CN¥238.44 Million | ▼ -28.7% |
| 2023 | 0.16x | CN¥1.52 Billion | CN¥240.04 Million | ▼ -38.4% |
| 2022 | 0.26x | CN¥2.07 Billion | CN¥530.62 Million | ▼ -28.3% |
| 2021 | 0.36x | CN¥1.74 Billion | CN¥622.38 Million | ▼ -17.7% |
| 2020 | 0.44x | CN¥1.59 Billion | CN¥692.04 Million | ▼ -71.8% |
| 2019 | 1.54x | CN¥698.39 Million | CN¥1.08 Billion | ▲ +39.3% |
| 2018 | 1.11x | CN¥1.45 Billion | CN¥1.60 Billion | ▼ -6.1% |
| 2017 | 1.18x | CN¥1.24 Billion | CN¥1.46 Billion | ▼ -48.2% |
| 2016 | 2.28x | CN¥775.90 Million | CN¥1.77 Billion | ▼ -13.0% |
| 2015 | 2.62x | CN¥736.17 Million | CN¥1.93 Billion | ▼ -30.7% |
| 2014 | 3.78x | CN¥571.04 Million | CN¥2.16 Billion | ▼ -6.1% |
| 2013 | 4.02x | CN¥527.25 Million | CN¥2.12 Billion | ▼ -7.4% |
| 2012 | 4.34x | CN¥375.75 Million | CN¥1.63 Billion | ▲ +76.4% |
| 2011 | 2.46x | CN¥525.31 Million | CN¥1.29 Billion | ▲ +52.4% |
| 2010 | 1.62x | CN¥509.18 Million | CN¥823.08 Million | ▼ -11.3% |
| 2009 | 1.82x | CN¥472.85 Million | CN¥861.67 Million | ▼ -37.8% |
| 2008 | 2.93x | CN¥221.28 Million | CN¥648.25 Million | ▲ +309.2% |
| 2007 | 0.72x | CN¥437.72 Million | CN¥313.34 Million | ▼ -75.5% |
| 2006 | 2.92x | CN¥108.03 Million | CN¥315.67 Million | ▲ +23.4% |
| 2005 | 2.37x | CN¥113.53 Million | CN¥268.75 Million | ▲ +137.0% |
| 2004 | 1.00x | CN¥312.93 Million | CN¥312.52 Million | ▲ +13.5% |
| 2003 | 0.88x | CN¥288.45 Million | CN¥253.90 Million | ▼ -56.3% |
| 2002 | 2.01x | CN¥120.82 Million | CN¥243.39 Million | ▼ -47.5% |
| 2001 | 3.84x | CN¥69.14 Million | CN¥265.33 Million | ▲ +5.4% |
| 2000 | 3.64x | CN¥55.70 Million | CN¥202.76 Million | ▼ -0.3% |
| 1999 | 3.65x | CN¥32.64 Million | CN¥119.23 Million | — |